Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTH and Risedronate for Glucocorticoid-Induced Osteoporosis
NCT00221299Phase 4Completed
- Sponsor
- University of California, Davis
- Start
- Sep 2005
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of teriparatide and risedronate in glucocorticoid-induced osteoporosis (GIOP) (4 arms), sponsored by University of California, Davis. Primary endpoint: Bone Mineral Density at 2 years. Started Sep 2005; status: completed.
02
Drugs
teriparatiderisedronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT00221299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221299.